BeOne Medicines Ltd. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BeOne Medicines Ltd. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $18.17M | Feb 28, 2018 |
| FY2017 | Sep 30, 2017 | $220.21M | Feb 28, 2018 |
| FY2017 | Dec 31, 2016 | $1.07M | Feb 28, 2018 |
| FY2017 | Jun 30, 2016 | $393.0K | Feb 28, 2018 |
| FY2017 | Mar 31, 2016 | $677.0K | Feb 28, 2018 |
| FY2016 | Dec 31, 2015 | $4.68M | Mar 22, 2017 |
| FY2016 | Sep 30, 2015 | $1.38M | Mar 22, 2017 |
| FY2016 | Jun 30, 2015 | $1.38M | Mar 22, 2017 |
| FY2016 | Mar 31, 2015 | $1.38M | Mar 22, 2017 |
| FY2016 | Dec 31, 2014 | $13.04M | Mar 22, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.34B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.81B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.46B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.42B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.18B | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | $100.10M | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | $91.08M | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | $65.64M | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | $52.06M | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $56.89M | Feb 25, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.67B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.22B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.08B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.13B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.01B | Feb 26, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $286.93M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($644.79M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($881.71M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($2.00B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($1.46B) | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | ($472.75M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($425.22M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($335.20M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($363.74M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($388.06M) | Feb 25, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($568.20M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($1.21B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($1.79B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($1.44B) | Feb 26, 2024 |
| FY2020 | Dec 31, 2020 | ($484.91M) | Feb 25, 2021 |
| FY2020 | Sep 30, 2020 | ($440.14M) | Feb 25, 2021 |
| FY2020 | Jun 30, 2020 | ($358.88M) | Feb 25, 2021 |
| FY2020 | Mar 31, 2020 | ($373.76M) | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | ($388.04M) | Feb 25, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.15B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.95B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.78B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.64B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $1.46B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.29B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $927.34M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $679.01M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $269.02M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $98.03M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.08B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $1.83B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $1.51B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.28B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $990.12M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $600.18M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $388.25M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $195.39M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $62.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $20.10M | Feb 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.13B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($140.63M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($1.16B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | ($1.50B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($1.30B) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | ($1.28B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($750.27M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($547.72M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $12.75M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | ($89.51M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $185.84M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $492.66M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $561.90M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $325.43M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $262.94M | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $117.51M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $89.61M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $70.28M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $46.37M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $23.50M | Feb 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.19B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.92B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.81B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $6.38B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $8.54B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.60B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $1.61B | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $2.25B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.05B | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $405.81M | Feb 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.83B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.59B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.27B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.00B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | $2.40B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $1.73B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $633.93M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $496.04M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $362.25M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $52.91M | Feb 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.36B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.33B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.54B | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $4.38B | Feb 26, 2026 |
| FY2024 | Dec 31, 2021 | $6.13B | Feb 27, 2025 |
| FY2021 | Dec 31, 2020 | $3.87B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $962.21M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $1.74B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $669.81M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $352.91M | Feb 28, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $109.0K | Feb 27, 2023 |
| FY2022 | Dec 31, 2021 | $109.0K | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $109.0K | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $109.0K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $109.0K | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $109.0K | Feb 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.32B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.61B) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($7.96B) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($7.08B) | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | ($5.08B) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($3.55B) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.96B) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($1.01B) | Mar 2, 2020 |
| FY2018 | Jan 1, 2018 | ($333.45M) | Feb 28, 2019 |
| FY2018 | Dec 31, 2017 | ($330.52M) | Feb 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.55B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.63B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $3.17B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.87B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.38B | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | $1.38B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $618.01M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $712.94M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $239.60M | Mar 2, 2020 |
| FY2018 | Dec 31, 2016 | $87.51M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $836.37M | Feb 26, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Feb 28, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Feb 28, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Feb 28, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 26, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2018 | Dec 31, 2017 | 0 | Feb 28, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Feb 28, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Feb 28, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.44B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 1.39B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 1.36B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 1.36B | Feb 26, 2024 |
| FY2022 | Dec 31, 2021 | 1.33B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 1.19B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 801.34M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 776.26M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 592.07M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 515.83M | Feb 28, 2018 |